CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation
Weijia Yu, Li Jiang · 2026
Read CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation by Weijia Yu, Li Jiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13352717.txt.
Description
Weijia Yu and Li Jiang trace in 2026 how support cells around a breast tumor help it resist a key targeted drug. The drug, trastuzumab, treats HER2-positive breast cancer, yet resistance is common. Neighbor cells called fibroblasts ship tiny parcels that may carry the resistance signal.
Parcels from tumor fibroblasts, unlike those from normal ones, switch on a growth path in cancer cells. That path raises a protein that steadies HER2 on the cell surface, so the drug loses its grip. Blocking the path with a known drug restores response in tests. Mouse tumors confirm the chain in living tissue. The work names a fresh target for keeping the drug effective longer.
Catalog record
| CREATOR | Weijia Yu, Li Jiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |